Search results
Woman Thought Baby's Facial Feature Was Trait from Dad, Then Realizes It's Symptom of Childhood...
People via Yahoo News· 14 hours agoFollowing a series of tests and a "week of nerves," Lydia...New Orleans-based genetics specialist,...
New hope for those living with Sickle Cell Disorder thanks to experimental gene treatment
WSB-TV 2 Atlanta· 6 days agoThe treatment is a gene cell therapy recently approved by the U.S. Food and Drug Administration. For...
Risk of secondary cancers after CAR-T cell therapy low, according to large study
Medical Xpress· 1 day agoA large study by researchers at Stanford Medicine has found that the risk of secondary blood cancers...
ECT for depression: Benefits, risks, and procedure
Medical News Today· 3 days agoElectroconvulsive therapy (ECT) is an alternative treatment for people with depression who have not responded to standard medication. Depression is a...
Study Elucidates Skin Signs of VEXAS Syndrome
Medscape· 2 hours agoSkin manifestations are common in the vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome and present early in the disease course....
Sernova Provides Update on Public Offering
NewMediaWire via Yahoo Finance· 1 day agoLONDON, Ontario and BOSTON, Massachusetts - (NewMediaWire) - June 12, 2024 - Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage...
2 Healthcare Stocks to Buy Hand Over Fist in June
Motley Fool via Yahoo Finance· 2 days agoCF is a rare genetic disorder that causes damage to various internal organs. Vertex's leadership...innovating, as evidenced by positive phase 3 data for...
FDA Expands Repotrectinib Label
Medscape· 1 day agoThe new accelerated approval for the TKI was based on the overall response rate in 48 patients.
Cathie Wood Invests In 2 Biotechnology Stocks – Are They Worth Buying?
Benzinga via Yahoo Finance· 7 days agoWith her ARK Innovation ETF (ARKK: NYSE Arca), Cathie Wood makes large wagers on biotech businesses...
A Drug to Slow Alzheimer’s Is Finally Available. How Are Patients Faring?
New York Times· 4 days agoAs the F.D.A. considers a new Alzheimer’s medication, we asked experts how the rollout of a similar...